Adaptive seamless phase II/III designs - Background, operational aspects, and examples

被引:83
作者
Maca, Jeff
Bhattacharya, Suman
Dragalin, Vladimir
Gallo, Paul
Krams, Michael
机构
[1] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源
DRUG INFORMATION JOURNAL | 2006年 / 40卷 / 04期
关键词
adaptive designs; seamless designs;
D O I
10.1177/216847900604000412
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Adaptive seamless designs have been considered as one possible way to shorten the time and patient exposure necessary to discover, develop, and demonstrate the benefits of a new drug. We introduce the concept of adaptive designs and describe the current statistical methodologies that relate to adaptive seamless designs. We also describe the decision process involved with seamless designs and present some illustrative examples.
引用
收藏
页码:463 / 473
页数:11
相关论文
共 29 条
[21]   Implementing adaptive designs: Logistical and operational considerations [J].
Quinlan, Judith A. ;
Krams, Michael .
DRUG INFORMATION JOURNAL, 2006, 40 (04) :437-444
[22]   Drop-the-losers design: Normal case [J].
Sampson, AR ;
Sill, MW .
BIOMETRICAL JOURNAL, 2005, 47 (03) :257-268
[23]  
SCHAID DJ, 1990, BIOMETRIKA, V77, P659
[24]   Point estimates and confidence regions for sequential trials involving selection [J].
Stallard, N ;
Todd, S .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2005, 135 (02) :402-419
[25]   Sequential designs for phase III clinical trials incorporating treatment selection [J].
Stallard, N ;
Todd, S .
STATISTICS IN MEDICINE, 2003, 22 (05) :689-703
[26]   A 2-STAGE DESIGN FOR CHOOSING AMONG SEVERAL EXPERIMENTAL TREATMENTS AND A CONTROL IN CLINICAL-TRIALS [J].
THALL, PF ;
SIMON, R ;
ELLENBERG, SS .
BIOMETRICS, 1989, 45 (02) :537-547
[27]   A new clinical trial design combining phases 2 and 3: Sequential designs with treatment selection and a change of endpoint [J].
Todd, Susan ;
Stallard, Nigel .
DRUG INFORMATION JOURNAL, 2005, 39 (02) :109-118
[28]  
*US FDA, 2006, CHALL OPP CRIT PATH
[29]  
US Food and Drug Administration, 2006, GUID CLIN TRIAL SPON